Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison Between the Efficacy of Intralesional Rituximab Versus Intralesional Triamcinolone in the Treatment Refractory Pemphigus Vulgaris Lesions: A Randomized Clinical Trial Publisher Pubmed



Iraji F1 ; Danesh F1 ; Faghihi G1 ; Siadat A1 ; Mokhtari F1 ; Talakoob M1 ; Hafezi H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: International Immunopharmacology Published:2019


Abstract

Background: Pemphigus Vulgaris (PV) is a vesiculobullous autoimmune disorder characterized by production of autoantibody against cellular adhesion molecules. The treatment of PV is based on the use of systemic corticosteroid along with immunosuppressive therapy, but sometimes there are limited resistant lesions not responding to conventional systemic therapy. This double-blind, randomized clinical trial was designed to evaluate the efficacy of intralesional rituximab versus triamcinolone in treatment of the refractory scalp and mucosal pemphigus lesions. Methods: 2 refractory lesions of PV were selected in 21 patients, and they were randomly assigned to two groups to be treated with either intralesional triamcinolone or rituximab for 2 times at one-month interval. All of the patients were under treatment with prednisolone and azathioprine. Patients were visited at the baseline, 1 and 6 months after treatment, and all information including demographic characteristics of the patients, Pemphigus Vulgaris Lesion Severity Score (PVLSS), Epithelialization Index (EI) and patient's satisfaction (using Visual Analogue Scale (VAS)) were obtained. The collected data were analyzed using SPSS software (ver18). Results: The results showed that, both rituximab and triamcinolone were effective in treatment of the refractory PV lesions (p < 0.05). However, there was no significant difference between the effect of intralesional rituximab and triamcinolone (p > 0.05). In addition, no side effect was observed in both groups. Conclusion: Regarding the results of the present study, the use of intralesional rituximab can be suggested for treatment of the resistant PV lesions as an alternative to intralesional triamcinolone or using more aggressive systemic therapy. © 2019
Related Docs
View other Related Docs
1. The Use of Oral Cyclophosphamide With Dexamethasone Pulse Therapy in the Treatment of Pemphigus Vulgaris, Journal of Dermatological Treatment (2007)
2. Pimecrolimus 1% Cream in the Treatment of Cutaneous Lesions of Pemphigus Vulgaris: A Double-Blind, Placebo-Controlled Clinical Trial, Journal of Drugs in Dermatology (2010)
3. The Efficacy of Acyclovir in Treatment of the Pemphigus Vulgaris, Journal of Research in Medical Sciences (2013)
4. The Efficacy of Nicotinamide Gel 4% As an Adjuvant Therapy in the Treatment of Cutaneous Erosions of Pemphigus Vulgaris, Dermatologic Therapy (2010)
5. Healing Effect of Pilocarpine Gel 4% on Skin Lesions of Pemphigus Vulgaris, International Journal of Dermatology (2006)
6. Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment, Iranian Journal of Pharmaceutical Research (2017)
7. Immunohistochemistry for Immunoglobulin G4 in the Diagnosis of Pemphigus, Indian Journal of Dermatology (2019)
8. Pemphigus Vulgaris in a Patient With Multiple Sclerosis: A Case Report With 7 Years of Follow Up, Journal of Research in Dental and Maxillofacial Sciences (2023)
Experts (# of related papers)
View all Related Experts
Ali Asilian (7)
Gita Faghihi (6)
Other Related Docs
9. Interventions for Bullous Pemphigoid: An Updated Systematic Review of Randomized Clinical Trials, Medical Journal of the Islamic Republic of Iran (2021)
10. Demographic, Clinical, and Paraclinical Characteristics of Patients With Pemphigus Vulgaris Needing Hospital Admission During the Years 2006-2017, Journal of Isfahan Medical School (2018)
11. Pemphigus Vulgaris in Iran: Epidemiology and Clinical Profile., Skinmed (2006)
12. Evaluation of Interleukin-1Α, Interleukin-10, Tumor Necrosis Factor-Α and Transforming Growth Factor-Β in the Serum of Patients With Pemphigus Vulgaris, Journal of Contemporary Dental Practice (2015)
13. Comparing the Efficacy of Topical Clobetasol 0.05% Plus 5-Fluorouracil 5% Cream Vs. Topical Clobetasol 0.05% Alone in Treatment of Vitiligo, Journal of Research in Medical Sciences (2012)
14. Persistent Nasal Skin Lesions in Pemphigus Patients and the Role of Methotrexate in Treatment: A Case Series Study, Dermatology Practical and Conceptual (2025)
15. Epidemiological Survey of the Patients With Bullous Pemphigoid Hospitalized in Alzahra Hospital, Isfahan, Iran, During the Years 2006-2015, Journal of Isfahan Medical School (2019)
16. Successful Treatment of Pemphigus Vulgaris With the Extensive Mucocutaneous Lesions in an Elderly Patient, Iranian Red Crescent Medical Journal (2014)
17. The Effect of L-Carnitine Supplementation on Serum Levels of Omentin-1, Visfatin and Sfrp5 and Glycemic Indices in Patients With Pemphigus Vulgaris: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Phytotherapy Research (2020)
18. Study of Apoptosis in Oral Pemphigus Vulgaris Using Immunohistochemical Marker Bax and Tunel Technique, Journal of Oral Pathology and Medicine (2013)
19. Clindamycin Lotion Alone Versus Combination Lotion of Clindamycin Phosphate Plus Tretinoin Versus Combination Lotion of Clindamycin Phosphate Plus Salicylic Acid in the Topical Treatment of Mild to Moderate Acne Vulgaris: A Randomized Control Trial, Indian Journal of Dermatology, Venereology and Leprology (2009)
20. Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis With Polyangiitis: A Systematic Review of Case Reports, Current Rheumatology Reviews (2024)
21. Frequency and Correlation of Peripheral and Tissue Eosinophilia With Clinical Manifestations in Patients With Bullous Pemphigoid, Dermatology Practical and Conceptual (2024)